learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
1 / 1 resultsResearch
5 / 18 results
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey Among Dermatologists in Saudi Arabia
Many dermatologists in Saudi Arabia recommend vitamins and minerals for hair loss, often based on personal experience rather than strong evidence.
research Bioengineered Plants as a Source of Omega-3 Fatty Acids
Genetically modified plants could be an important source of omega-3 fats to meet global needs.
research Spigo Nardo: From the Este Herbarium a Possible Solution for Its Taxonomical Attribution
Researchers concluded that "spigo nardo" is the Himalayan plant Nardostachys jatamansi, used historically in medicine and cosmetics, now critically endangered.
research Review of the 2024 American Academy of Dermatology Annual Meeting
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
Community Join
5 / 77 resultscommunity Is PP405 formula available in grey market?
The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.
community Update for PP405 - phase 2b underway
PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.
community PP405 Drug in Action: Picture From Official Company Website
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
community Gray market sources to get gt20029 or pp405?
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
community VDPHL-01 is Overrated and Ridiculous. This is just Oral Minoxidil.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.